Inmazeb
Active Ingredient(s): Atoltivimab + Odesivimab + MaftivimabFDA Approved: * October 14, 2020
Pharm Company: * REGENERON PHARMACEUTICALS
Category: Antiviral
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Inmazeb Overview
Atoltivimab/maftivimab/odesivimab, sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus (Ebola virus).[2] It contains atoltivimab, maftivimab, and odesivimab-ebgn.[2] The most common symptoms include fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting; however, these are also common symptoms of Ebola virus infection.[2][3&...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Atoltivimab/maftivimab/odesivimab
Recent Inmazeb Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Atoltivimab + Odesivimab + Maftivimab
- Solution: 16.7mg/1ml
NDC Database Records for Inmazeb: (1 result)
Sorted by National Drug Code- 61755-018 Inmazeb Intravenous Injection, Solution by Regeneron Pharmaceuticals, Inc.